Emerging drugs for epilepsy

Expert Opinion on Emerging Drugs

Volumn 12, Issue 3, 2007, Pages 407-422

  Kwan, Patrick ^a   Brodie, Martin J ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antiepileptic drug; Becampanel; Brivaracetam; Carisbamate; DP VPA; Eliscarbazepine; Epilepsy; Fluorofclbamate; Ganaxolone; Lacosamide; NS 1209; Retigabine; Rufinamide; Safinamide; Seizure; Seletracetam; Stiripentol; Talampanel; Valpromide; Valrocemide

Indexed keywords

ANTICONVULSIVE AGENT; BECAMPANEL; BENZODIAZEPINE; BIA 2093; BRIVARACETAM; CARBAMAZEPINE; CARBAMIC ACID 2 (2 CHLOROPHENYL) 2 HYDROXYETHYL ESTER; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FLUOROFELBAMATE; GABAPENTIN; GANAXOLONE; HARKOSERIDE; LAMOTRIGINE; LICARBAZEPINE; NS 1209; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RETIGABINE; SELETRACETAM; TALAMPANEL; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE; NEW DRUG;

AGRANULOCYTOSIS; ALLERGIC REACTION; APLASTIC ANEMIA; ATAXIA; DIPLOPIA; DISEASE CLASSIFICATION; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; ECONOMIC ASPECT; EPILEPSY; EPILEPTIC STATE; FATIGUE; GABAERGIC SYSTEM; GINGIVA HYPERTROPHY; HEADACHE; HIRSUTISM; HUMAN; INJURY; LIVER FAILURE; LIVER NECROSIS; MACULOPAPULAR RASH; MORTALITY; NAUSEA; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SOCIAL PSYCHOLOGY; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TERATOGENICITY; TOXIC EPIDERMAL NECROLYSIS; VISUAL FIELD DEFECT; WEIGHT GAIN; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; DRUG DESIGN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUGS, INVESTIGATIONAL; EPILEPSY; HUMANS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34748887734     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.12.3.407     Document Type: Review

References (98)

1. SANDER JWAS, SHORVON SD: Epidemiology of the epilepsies. J. Neurol. Neurosurg. Psychiatry (1996) 61:433-443.
2. HAUSER WA, ANNEGERS JF, ROCCA WA: Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin. Proc. (1996) 71:576-586.
3. KWAN P, BRODIE MJ: Early identification of refractory epilepsy. N. Engl. J. Med. (2000) 342:314-319.
4. KWAN P, SANDER JW: The natural history of epilepsy: an epidemiological view. J. Neurol. Neurosurg. Psychiatry (2004) 75:1376-1381.
5. FISHER RS, VAN EMDE BOAS W, BLUME W et al.: Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia (2005) 46:470-472.
6. COMMISSION ON CLASSIFICATION AND TERMINOLOGY OF THE INTERNATIONAL LEAGUE AGAINST EPILEPSY: Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia (1981) 22:489-501.
7. COMMISSION ON CLASSIFICATION AND TERMINOLOGYOF THE INTERNATIONAL LEAGUE AGAINST EPILEPSY: Proposal for revised clinical classification of epilepsies and epileptic syndromes. Epilepsia (1989) 30:389-399.
8. MCCORMICK DA, CONTRERAS D: On the cellular and network bases of epileptic seizures. Ann. Rev. Physiol. (2001) 63:815-846.
9. ROGAWSKI MA, LÖSCHER W: The neurobiology of antiepileptic drugs. Nat. Rev. (2004) 5:553-564.
10. MULLEY JC, SCHEFFER IE, PETROU S, BERKOVIC SF: Channelopathies as a genetic cause of epilepsy. Curr. Opin. Neurol. (2003) 16:171-176.
11. TOMSON T, BEGHI E, SUNDQVIST A, JOHANNESSEN SI: Medical risks in epilepsy: a review with focus on physical injuries, mortality, traffic accidents and their prevention. Epilepsy Res. (2004) 60:1-16.
12. LAWN ND, BAMLET WR, RADHAKRISHNAN K, O'BRIEN PC, SO EL: Injuries due to seizures in persons with epilepsy: a population-based study. Neurology (2004) 63:1565-1570.
13. GAITATZIS A, JOHNSON AL, CHADWICK DW, SHORVON SD, SANDER JW: Life expectancy in people with newly diagnosed epilepsy. Brain (2004) 127:2427-2432.
14. MOHANRAJ R, NORRIE J, STEPHEN LJ et al.: Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study. Lancet Neurol. (2006) 5:481-487.
15. BAZIL CWL: Comprehensive care of the epilepsy patient - control, comorbidity, and cost. Epilepsia (2004) 45(Suppl. 6):3-12.
16. SCHACHTER SC: Quality of life for patients with epilepsy is determined by more than seizure control: the role of psychosocial factors. Expert Rev. Neurother. (2006) 6:111-118.
17. BEGLEY CE, FAMULARI M, ANNERGERS JF et al.: The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia (2000) 41:342-351.
18. KWAN P, BRODIE MJ: Combination therapy in epilepsy: when and what to use? Drugs (2006) 66:1817-1829.
19. FRENCH JA, KANNER AM, BAUTISTA J et al.: Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology (2004a) 62:1252-1260.
20. MARSON AG, WILLIAMSON PR, HUTTON JL, CLOUGH HE, CHADWICK DW: Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia (2002) 43:505-513.
21. KWAN P, BRODIE MJ: Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia (2004) 45:1141-1149.
22. KWAN P, BRODIE MJ: Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology (2003) 60(Suppl. 4):S2-S12.
23. BRODIE MJ, PERUCCA E, RYVLIN P, BEN-MENACHEM E, MEENCKE H-J; FOR THE LEVETIRACETAM MONOTHERAPY STUDY GROUP: Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology (2007) 68:402-408.
24. GLAUSER T, BEN-MENACHEM E, BOURGEOIS B et al.: ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia (2006) 47:1094-1120.
25. MARSON AG, AL-KHARUSI A, ALWAIDH M et a.: The SANAD study of effectiveness of valproate, lamotrigine and topiramate for generalised and unclassified epilepsy: an unblinded randomised controlled trial. Lancet (2007) 369:1016-1026.
26. MARSON AG, AL-KHARUSI AM, ALWAIDH M et al.: The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet (2007) 369:1000-1015.
27. MOHANRAJ R, BRODIE MJ: Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur. J. Neurol. (2006) 13:277-282.
28. MOHANRAJ R, BRODIE MJ: Measuring the efficacy of antiepileptic drugs. Seizure (2003) 12:413-443.
29. FRENCH JA, KANNER AM, BAUTISTA J et al.: Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology (2004b) 62:1261-1273.
30. ARROYO S, DE LA MORENA A: Life-threatening adverse events of antiepileptic drugs. Epilepsy Res. (2001) 47:155-174.
31. WYSZYNSKI DF, NAMBISAN M, SURVE T, ALSDORF RM, SMITH CR, HOLMES LB; FOR THE ANTIEPILEPTIC DRUG PREGNANCY REGISTRY: increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology (2005) 64:961-965.
32. ARTAMA M, AUVINEN A, RAUDASKOSKI T, ISOJARVI I, ISOJARVI J: Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology (2005) 64:1874-1878.
33. MORROW J, RUSSELL A, GUTHRIE E et al.: Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatry (2006) 77:193-198.
34. MEADOR KJ, BAKER GA, FINNELL RH et al.: In utero antiepileptic drug exposure: fetal death and malformations. Neurology (2006) 67:407-412.
35. TIAN G-F, AZMI H, TAKANO T et al.: Astrocytic basis of epilepsy. Nat. Med. (2005) 11:973-981.
36. KWAN P, SILLS GJ, BRODIE MJ: The mechanisms of action of commonly used antiepileptic drugs. Pharmacol. Ther. (2001) 90:21-34.
37. LYNCH BA, LAMBENG N, NOCKA K et al.: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. USA (2004) 101:9861-9866.
38. LÖSCHER W, SCHMIDT D: Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. (1988) 2:145-181.
39. STABLES JP, BERTRAM E, DUDEK FE et al.: Therapy discovery for pharmacoresistant epilepsy and for disease-modifying therapeutics: summary of the NIH/NINDS/AES models II workshop. Epilepsia (2003) 44:1472-1478.
40. SMITH M, WILCOX KS, WHITE HS: Discovery of antiepileptic drugs. Neurotherapeutics (2007) 4:12-17.
41. WHITE HS: Comparative anticonvulsant and mechanistic profile of established and newer antiepileptic drugs. Epilepsia (1999) 40(Suppl. 5):S2-S10.
42. LÖSCHER W, HONACK D: Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol. (1993) 232:147-158.
43. ROGAWSKI MA: Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. (2006) 69:273-294.
44. POLLARD JR, FRENCH J: Antiepileptic drugs in development. Lancet Neurol. (2006) 5:1064-1067.
45. KENDA BM, MATAGNE AC, TALAGA PE et al.: Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J. Med. Chem. (2004) 47:530-549.
46. BIALER M, JOHANNESSEN SI, KUPFERBERG HJ, LEVY RH, PERUCCA E, TOMSON T: Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. (2004) 61:1-48.
47. VON ROSENSTEIL P: Brivaracetam (UCB24714). Neurothempeutics (2007) 4:84-87.
48. BIALER M, JOHANNESSEN SI, KUPFERBERG HJ, LEVY RH, PERUCCA E, TOMSON T: Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res. (2007) 73:1-52.
49. KASTELEIJN-NOLST TRENITÈDGA, PARAIN D, MASNOU P, GENTON P, STEINHOFF BJ, HIRSCH E: Proof of principle in the new AED ucb 34714; use of the photosensitivity model. Epilepsia (2004) 45(Suppl. 7):309.
50. KASTELEIJN-NOLST TRENITÈ D, ABOU-KHALIL B, FRENCH J et al.: Proof of principle in the new antiepileptic drug seletracetam (ucb 44212) in the photosensitivity model. Presented in 1st North American Epilepsy Congress, San Diego, CA. (1-5 December 2006).
51. BONIFACIO MJ, SHERIDAN RD, PARADA A, CUNHA RA, PATMORE L, SOARES-DA-SILVA P: Interaction of the novel anticonvulsant, BIA2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia (2001) 42:600-608.
52. WUTTKE TV, LERCHE H: Novel anticonvulsant drugs targeting voltage-dependent ion channels. Expert Opin. Investig. Drugs (2006) 15:1167-1177.
53. ELGER C, BIALER M, CRAMER JA, MAIA J, ALMEIDA L, SOARES-DA-SILVA P: Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia (2007) 48:497-504.
54. ALMEIDA L, SOARES-DA-SILVA P: Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics (2007) 4:88-96.
55. POPOVIC M, NIERKENS S, PIETERS R, UETRECHT J: Investigating the role of 2-phenylpropenal in felbamate-induced idiosyncratic drug reactions. Chem. Res. Toxicol. (2004) 17:1568-1576.
56. ROECKLEIN BU, SACKS HJ, MORTKO H, STABLES J: Fluorofelbamate. Neurotherapeutics (2007) 4:97-101.
57. WHITE HS, SRIVASTAVA A, KLEIN B et al.: The novel investigational neuromodulator RWJ 333369 displays a broad-spectrum anticonvulsant profile in rodent seizure and epilepsy models. Presented in 1st North American Epilepsy Congress, San Diego, CA (1-5 December 2006).
58. TRENITE DG, FRENCH JA, HIRSCH E et al.: Evaluation of carisbamate, a novel antiepileptic drug in photosensitive epilepsy: an exploratory, placebo-controlled study. Epilepsy Res. (In Press).
59. NOVAK GP, KELLEY M, ZANNIKOS P, KLEIN B: Carisbamate (RWJ-333369). Neurotherapeutics (2007) 4:106-109.
60. BIALER M, YAGEN B: Valproic acid: second generation. Neurotherapeutics (2007) 4:130-137.
61. BIALER M, JOHANNESSEN SI, KUPFERBERG HJ, LEVY RH, LOISEAU P, PERUCCA E, TOMSON T: Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. (2002) 51:31-71.
62. RUNDFELDT C, NETZER R: The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci. Lett. (2000) 282:73-76.
63. + channels and the molecular pathogenesis of epilepsy: implications for therapy. Trends Neurosci. (2000) 23:393-398.
64. BIEVERT C, SCHROEDER BC, KUBISCH C et al.: A potassium channel mutation in neonatal human epilepsy. Science (1998) 279:403-406.
65. SINGH NA, CHARLIER C, STAUFFER D et al.: A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat. Genet. (1998) 18:25-29.
66. CHARLIER C, SINGH NA, RYAN SG et al.: A pore mutation in a novel KQT-like potassium channel gene in an idiopachic epilepsy family. Nat. Genet. (1998) 18:53-55.
67. ROSTOCK A, TOBER C, RUNDFELDT C et al.: D-23129: a new anticonvulsant with a braod spectrum activity in animal models of epileptic seizures. Epilepsy Res. (1996) 23:211-223.
68. PORTER RJ, NOHRIA V, RUNDFELDT C: Retigabine. Neurotherapeutia (2007) 4:149-154.
69. PORTER RJ, PARTIOT A, SACHDEO R, NOHRIA V, ALVES WM; FOR THE 205 STUDY GROUP: Randomized, multicentre, dose-ranging trial of retigabine for partial-onset seizures. Neurology (2007) 68:1197-1204.
70. HOWES JF, BELL C: Talampanel. Neunthempeutics (2007) 4:126-129.
71. SOLYOM S, TARNAWA I: Non-competitive AMPA antagonists of 2,3-benzodiazepine type. Curr. Pharm. Des. (2002) 8:913-939.
72. CHAPPELL AS, SANDER JW, BRODIE MJ et al.: A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology (2002) 58:1680-1682.
73. FETELL MR, RAMSAY RE, BELL C, TANG S: Efficacy of the AMPA antagonist talampanel in refractory partial epilepsy J. Neurol. Sci. (2005) (Suppl. 1):A238 (Abstract).
74. REDDY DS: Pharmacology of endogenous neuroactive steroids. Crit. Rev. Neurobiol. (2003) 15:197-234.
75. REDDY DS, ROGAWSKI MA: Chronic treatment with neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J. Pharmacol. Exp. Ther. (2000) 295:1241-1248.
76. NOHRIA V, GILLER E: Ganaxolone. Neurotherapy (2007) 4:102-105.
77. ERRINGTON AC, COYNE L, STÖHR T et al.: Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology (2006) 50:1016-1029.
78. THOMAS D, SCHARFENECKER U, SCHILTMEYER B, DOTY P, CAWELLO W, R HORSTMANN R: Low potential for drug-drug-interaction of lacosamide. Presented in 1st North American Epilepsy Congress, San Diego, CA (1-5 December 2006).
79. HALASZ P, KALVIAINEN R, MAZURKIEWICZ-BELDZINSKA M, ROSENOW F, DOTY P, SULLIVAN T: Lacosamide: efficacy and safety as oral adjunctive therapy in adults with partial seizures. Presented in 1st North American Epilepsy Congress, San Diego, CA (1-5 December 2006).
80. BEN-MENACHEM E, BITON V, JATUZIS D, ABOU-KHALIL B, DOTY P, RUDD GD: Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia (In Press).
81. KRAUSS G, BEN-MENACHEM E, MAMENISKIENE R, VAICIENE N, BROCK M, WHITESIDES J: Intravenous lacosamide (SPM 927) as replacement for oral lacosamide in subjects with partial seizures: a multicenter, open-label, inpatient safety and tolerability trial. Presented in 1st North American Epilepsy Congress, San Diego, CA (1 - 5 December 2006).
82. ARROYO S: Rufinamide. Neurotherapeutics (2007) 4:155-162.
83. DEEKS ED, SCOTT LJ: Rufinamide. CNS Drugs (2006) 20:751-760.
84. ALDENKAMP AP, ALPHERTS WCJ: The effects of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia (2006) 47:1153-1159.
85. ANONYMOUS: Rufinamide. GCP 33101, E 2080, RUF 331, Xilep. Drugs R. D. (2005) 6:249-252.
86. CHENG-HAKIMIAN A, ANDERSON GD, MILLER JW: Rufinamide: pharmacology, clinical trials, and role in clinical practice. Int. J. Clin. Pract. (2006) 60:1497-1501.
87. FARIELLO RG: Safinamide. Neurotherapeutics (2007) 4:110-116.
88. ANONYMOUS: Safinamide. FCE 26743, NW 1015, PNU 151774, PNU 151774E. Drugs R. D. (2004) 5:355-358.
89. QUILICHINI PP, CHIRON C, BEN-ARI Y, GOZLAN H: Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A-receptor channels. Epilepsia (2006) 47:706-716.
90. CHIRON C, MARCHAND MC, TRAN A et al.: Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndromededicated trial. STICLO study group. Lancet (2000) 356:1638-1642.
91. CHIRON C: Stiripentol. Neurotherapeutics (2007) 4:123-125.
92. KWAN P, BRODIE MJ: Refractory epilepsy: mechanisms and solutions. Expert Rev. Neurother. (2006) 6:397-406.
93. MELDRUM BS, ROGAWSKI MA: Molecular targets for antiepileptic drug development. Neurotherapeutics (2007) 4:18-61.
94. FISHER RS, HO J: Potential new methods for antiepileptic drug delivery. CNS Drugs (2002) 16:579-593.
95. LESCHZINER GD, ANDREW T, PIRMOHAMED M, JOHNSON MR: ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenom. J. (2007) 7:154-179.
96. KWAN P, BAUM L, WONG V et al.: Association between ABCB1 C3435T polymorphism and drug resistant epilepsy in Han Chinese. Epilepsy Behav. (In Press).
97. CHUNG WH, HUNG SI, HONG HS et al.: Medical genetics: a marker for Stevens-Johnson syndrome. Nature (2004) 428:486.
98. MAN CBL, KWAN P, BAUM L et al.: Association between HLA-B* 1502 allele and antiepileptic drugs-induced cutaneous reactions in Han Chinese. Epilepsia (2007) 48:1015-1018.